Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty

C. Colwell, M. Froimson, M. Mont, M. Ritter, R.Trousdale,
K. Buehler, A. Spitzer, T. Donaldson, D. Padgett.
The Journal of Arthroplasty, September 2012; 27(8):1417-1584

Findings: Based on the SAFE study, this model was constructed to evaluate any difference in cost-effectiveness between ActiveCare®+SFT and Lovenox® therapies.  The model analysis showed that in average ActiveCare®+SFT treatment cost USD365.90 less than the Lovenox® treatment per patient. The difference in therapy costs was primarily a result of major bleeding which had a significantly greater probability when Lovenox® was used.

Learn more on this study

What did the model compare?
A model was constructed to evaluate any difference in cost-effectiveness between ActiveCare®+SFT and Lovenox® therapies.

How was the model designed?
A model was designed based on VTE/DVT and bleeding rates from the SAFE study. The model included a decision tree analysis to measure the cost effectiveness of ActiveCare®+SFT vs. Lovenox® in terms of cost per adverse event ( DVT, PE , minor and major bleeding).The model cost parameters included medications, laboratory procedures, hospitalization, physician inpatient visit and physician outpatient visits.

Model Analysis Conclusion.
The model analysis showed that in average  ActiveCare®+SFT treatment  cost USD365,90 less than the Lovenox® treatment per patient. The difference in therapy costs  was primarily a result of major bleeding which had a significantly greater probability when Lovenox® was used (In the SAFE study) . Major bleeding leads to additional hospital stays, increased physician, nursing and pharmacy care, additional laboratory costs and blood transfusion. The additional cost to treat a major bleeding event was calculated to be $5363.13. In addition, major bleeding complication leads to prolonged hospital stay, extends patient recovery and healing time and exposes patient at risk to possible surgery, hematoma, infection and death.